Literature DB >> 10025923

Fas and Fas ligand interaction induces apoptosis in inflammatory myopathies: CD4+ T cells cause muscle cell injury directly in polymyositis.

T Sugiura1, Y Murakawa, A Nagai, M Kondo, S Kobayashi.   

Abstract

OBJECTIVE: To investigate the involvement of the Fas/Fas ligand (Fas/FasL) system in the inflammatory myopathies.
METHODS: Frozen muscle sections obtained from 7 patients with polymyositis (PM), 4 patients with dermatomyositis (DM), and 3 controls were studied by immunochemistry. Apoptosis was detected by DNA electrophoresis and in situ labeling using the TUNEL method.
RESULTS: Fas was detected on muscle fibers and infiltrating mononuclear cells (MNC) in 6 PM patients and 2 DM patients. FasL was expressed mainly on CD4+ T cells and some CD8+ T cells, and on macrophages surrounding Fas-positive muscles in 4 PM patients and 1 DM patient. In 3 of the 5 patients with FasL-positive MNC, the TUNEL method showed that both invaded myonuclei and MNC underwent apoptosis. Chromosomal DNA from the muscle tissue of these patients showed ladder formation.
CONCLUSION: Fas/FasL is involved in muscle cell apoptosis in at least 2 of the inflammatory myopathies, PM and DM. Although CD8+-mediated cytotoxicity is thought to be the main mechanism of muscle injury in PM, our data suggest that CD4+ T cells also directly cause muscle cell damage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025923     DOI: 10.1002/1529-0131(199902)42:2<291::AID-ANR11>3.0.CO;2-1

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  15 in total

1.  Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases.

Authors:  Stephan Seeliger; Thomas Vogl; Ingo Hubert Engels; J Michael Schröder; Clemens Sorg; Cord Sunderkötter; Johannes Roth
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

2.  CD4+ T lymphocytes mediate in vivo clearance of plasmid DNA vaccine antigen expression and potentiate CD8+ T-cell immune responses.

Authors:  Ralf Geiben-Lynn; John R Greenland; Kwesi Frimpong-Boateng; Nico van Rooijen; Avi-Hai Hovav; Norman L Letvin
Journal:  Blood       Date:  2008-09-10       Impact factor: 22.113

Review 3.  Apoptosis of skeletal muscle cells and the pathogenesis of myositis: a perspective.

Authors:  C C Liu; J M Ahearn
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

4.  Mechanisms of cell-mediated myocytotoxicity in the peripheral blood of patients with inflammatory myopathies.

Authors:  I Bank; A F Miranda; L Chess
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

Review 5.  Cell death, clearance and immunity in the skeletal muscle.

Authors:  C Sciorati; E Rigamonti; A A Manfredi; P Rovere-Querini
Journal:  Cell Death Differ       Date:  2016-02-12       Impact factor: 15.828

Review 6.  Pathogenesis of idiopathic inflammatory myopathies.

Authors:  Cecilia Grundtman; Ingrid E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

Review 7.  The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

8.  Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: impact of duration of untreated disease.

Authors:  Yongdong Zhao; Tamara O Fedczyna; Violet McVicker; Jan Caliendo; Honglin Li; Lauren M Pachman
Journal:  Clin Immunol       Date:  2007-08-20       Impact factor: 3.969

9.  Roles of proinflammatory cytokines and the Fas/Fas ligand interaction in the pathogenesis of inflammatory myopathies.

Authors:  Masahiro Kondo; Yohko Murakawa; Nanae Harashima; Shotai Kobayashi; Shuhei Yamaguchi; Mamoru Harada
Journal:  Immunology       Date:  2008-12-26       Impact factor: 7.397

10.  A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer.

Authors:  M Ferrand; A Galy; F Boisgerault
Journal:  Gene Ther       Date:  2014-07-17       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.